AKT1 and ovarian carcinoma: Human recombinant IGFBP2 activated the ERK signaling pathway and stimulated proliferation in glioblastoma cells (through an integrin β1-dependent mechanism) [33] and ovarian cancer cells [58] and was shown to increase ERK as well as AKT activation in breast cancer cells [23].